Price
No data yet.
Social Signal Score
Analyst Ratings
52 analystsRevenue
$1.31B+780.48%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Jacob Steven Leach
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 11,050
- Beta
- 1.42
- Country
- US
- Piotroski score
- 8 / 9 (Strong)
- Altman Z-score
- 7.42
Financials
Revenue
$1.31B+780.5%Net Income
$249.10MEBITDA
$388.70MFree Cash Flow
$184.50M+2573.9%EPS (diluted)
$0.64Shares Outstanding (diluted)
391.80M+16.5%Operating Expenses
$511.70MCash & Debt
$1.95BReturn of Capital
$603.60MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $4.66B | $836.30M | $2.14 |
| 2024 | $4.03B | $576.20M | $1.46 |
| 2023 | $3.62B | $541.50M | $1.44 |
| 2022 | $2.91B | $341.20M | $0.88 |
| 2021 | $2.45B | $216.90M | $0.56 |
| 2020 | $1.93B | $493.60M | $1.31 |
| 2019 | $1.48B | $101.10M | $0.28 |
| 2018 | $1.03B | $-127.10M | $-0.36 |
| 2017 | $718.50M | $-50.20M | $-0.15 |
| 2016 | $573.30M | $-65.60M | $-0.20 |
| 2015 | $402.00M | $-57.60M | $-0.18 |
| 2014 | $259.20M | $-22.40M | $-0.07 |
| 2013 | $160.00M | $-29.80M | $-0.10 |
| 2012 | $99.90M | $-54.50M | $-0.20 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $3.15
- Implied price
- $97.62
- Return from $86.41
- 2.5% a year
To earn 15.0% a year on these assumptions you'd need to buy at $48.54 — -43.8% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 21 | 26 | 31 | 36 | 41 |
|---|---|---|---|---|---|
| -2.0% | -14.0% | -10.2% | -7.0% | -4.2% | -1.7% |
| 3.0% | -9.6% | -5.7% | -2.3% | 0.7% | 3.3% |
| 8.0% | -5.2% | -1.1% | 2.5% | 5.6% | 8.4% |
| 13.0% | -0.8% | 3.5% | 7.2% | 10.5% | 13.4% |
| 18.0% | 3.6% | 8.1% | 12.0% | 15.4% | 18.4% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
50-71.01%Social Signal Score
Mentions (14)
- Newszacks.com·3d ago·Neutral
DXCM Report Highlights CGM Growth Opportunity in Type 2 Diabetes Care Dexcom sees room to expand CGM adoption as low awareness, reimbursement hurdles and rising GLP-1 use create new opportunities in Type 2 diabetes.
View source ↗ - Newszacks.com·6d ago·Positive
Here's Why DexCom (DXCM) is a Strong Growth Stock The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
View source ↗ - Newsbusinesswire.com·21d ago·Neutral
Dexcom Promotes Jereme Sylvain to Chief Operating Officer SAN DIEGO--(BUSINESS WIRE)--Dexcom Promotes Jereme Sylvain to Chief Operating Officer.
View source ↗ - Newszacks.com·21d ago·Positive
Here's Why You Should Retain DexCom Stock in Your Portfolio for Now DXCM's strong growth, G7 15 Day adoption and CONNECT trial could expand its CGM market opportunity despite reimbursement and competition risks.
View source ↗ - Newsseekingalpha.com·26d ago·Positive
DexCom, Inc. (DXCM) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript DexCom, Inc. (DXCM) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
View source ↗ - Newszacks.com·33d ago·Positive
Why DexCom (DXCM) is a Top Growth Stock for the Long-Term Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
View source ↗ - Newszacks.com·41d ago·Positive
Abbott vs. DexCom: Which CGM Stock Is the Better Buy Now? ABT edges DXCM on price-target upside and valuation, while both pursue CGM growth through innovation, adoption and strong liquidity.
View source ↗ - Newszacks.com·45d ago·Positive
Here's Why DexCom (DXCM) is a Strong Momentum Stock The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
View source ↗ - News (RSS)yahoo·52d ago·Neutral
Is Wall Street Bullish or Bearish on DexCom Stock?
View source ↗ - Newszacks.com·53d ago·Positive
Here's Why DexCom (DXCM) is a Strong Growth Stock Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
View source ↗ - Newszacks.com·54d ago·Positive
Is DXCM Stock Worth Buying as Growth Improves but Valuation Stretches? DexCom's broader CGM coverage, G7 15 Day rollout and rising margins support growth, but premium valuation, competition and litigation temper upside.
View source ↗ - Newszacks.com·54d ago·Positive
Can DexCom's Raised 2026 Outlook Sustain Stronger Margin Momentum? DexCom raises its 2026 revenue and margin outlook as G7 15 Day efficiencies lift profitability, while FX and transition costs remain key tests.
View source ↗ - Newszacks.com·54d ago·Positive
DXCM Rallies 52.5% in 3 Months. Can the Stock Keep Climbing From Here? DexCom's 52.5% three-month rally is backed by earnings growth and margin gains, but premium valuation, competition and litigation raise the bar.
View source ↗ - Newszacks.com·54d ago·Positive
DXCM Stock Up Nearly 35% YTD: Will the Uptrend Continue in the Rest of 2026? DXCM's 2026 rebound is backed by stronger growth, G7 15 Day adoption and broader CGM access, but competition and reimbursement remain key risks.
View source ↗
Earnings
Thu, Oct 29(in 3 weeks)
Consensus estimate $0.67 per share
Typical surprise +5.9% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Jul 30$0.70 vs $0.61beat
- Thu, Apr 30$0.56 vs $0.47beat
- Thu, Feb 12$0.68 vs $0.65beat
- Thu, Oct 30$0.61 vs $0.58beat
- Wed, Jul 30$0.48 vs $0.44beat
- Thu, May 1$0.32 vs $0.33miss
Estimates and results for DXCM via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by DXCM officers and directors.
- Bought
- $1.0m
- Sold
- $14.2m
2 trades
42 trades
- Stern Sadiesold
- Augustinos Nicholassold
- Brown Michael Jonsold
- Augustinos Nicholassold
- Sylvain Jereme Msold
- Stern Sadiesold
- Sayer Kevin Rsold
- Sayer Kevin Rsold
56 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Ro Khannahouse · CA17 · disclosed Jun 11, 2026 (41d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed May 13, 2026 (30d later)Buy$1,001 - $15,000
- John Boozmansenate · AR · disclosed Feb 15, 2026 (20d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Feb 10, 2026 (12d later)Buy$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Oct 13, 2025 (21d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Oct 3, 2025 (4d later)Sell$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Jul 9, 2025 (37d later)Buy$15,001 - $50,000
- Michael T. McCaulhouse · TX10 · disclosed Jul 9, 2025 (23d later)Sell$15,001 - $50,000
- Jefferson Shrevehouse · IN06 · disclosed Jun 23, 2025 (42d later)Sell$15,001 - $50,000
- Jefferson Shrevehouse · IN06 · disclosed Jun 23, 2025 (46d later)Buy$15,001 - $50,000
- Robert P. Bresnahanhouse · PA08 · disclosed Jun 10, 2025 (26d later)Buy$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed May 15, 2025 (37d later)Buy$50,001 - $100,000
- Jefferson Shrevehouse · IN06 · disclosed May 9, 2025 (32d later)Sell$15,001 - $50,000
- Robert P. Bresnahanhouse · PA08 · disclosed Apr 29, 2025 (21d later)Sell$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Apr 18, 2025 (36d later)Buy$15,001 - $50,000
- Robert P. Bresnahanhouse · PA08 · disclosed Mar 28, 2025 (31d later)Buy$1,001 - $15,000
- Kevin Hernhouse · OK01 · disclosed Jan 15, 2025 (15d later)Sell$50,001 - $100,000
- Ro Khannahouse · CA17 · disclosed Oct 8, 2024 (29d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Oct 8, 2024 (29d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Nov 8, 2023 (29d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.